Austco Healthcare (ASX: AHC): The Nurse-Call Tech Play

Aditi Sarkar

29 July 2026 10:45 PM AEST

Austco Healthcare (ASX: AHC): The Nurse-Call Tech Play

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Austco Healthcare (ASX: AHC) has quietly compounded revenue and earnings while lifting FY26 guidance.
The shares have attracted renewed interest in 2026, though any short-term price move should be weighed against the underlying business rather than treated as a verdict in itself.
Formerly listed as Azure Healthcare (ASX: AZV), the company rebranded to Austco and says its technology is deployed across more than 5,000 healthcare facilities worldwide, with operations spanning Australia, New Zealand, North America, Asia and the Middle East.
Austco's first-half FY26 result, for the six months to 31 December 2025 (released 18 February 2026), showed the model working.

Austco Healthcare (ASX: AHC) has quietly compounded revenue and earnings while lifting FY26 guidance. We look past the recent share-price move to what the nurse-call and clinical-workflow group's numbers actually show.

Company Overview

Port Melbourne-based Austco Healthcare designs, manufactures and installs nurse-call and clinical-communication systems for hospitals and aged-care facilities. Formerly listed as Azure Healthcare (ASX: AZV), the company rebranded to Austco and says its technology is deployed across more than 5,000 healthcare facilities worldwide, with operations spanning Australia, New Zealand, North America, Asia and the Middle East.

Recent Developments

Austco's first-half FY26 result, for the six months to 31 December 2025 (released 18 February 2026), showed the model working. Total revenue rose about 31% to $48.2 million, EBITDA jumped roughly 60% to $8.3 million, and net profit after tax climbed about 62% to $4.74 million. Basic earnings per share came in at 1.28 cents, up from 0.81 cents a year earlier.

Financial and Operational Snapshot

Austco carries a clean balance sheet. Cash stood at $15.2 million at 31 December 2025, up from $14.5 million at the FY25 close, and the business generated $9.2 million of operating cash flow in the half — a healthy conversion that funded growth without meaningful debt.

What May Be Watched Next

The clearest near-term catalyst is the planned deployment of Pulse Mobile to roughly 180 hospitals across Austco's largest US customer during the 2026 calendar year — a reference site that could support further North American penetration. The update also flagged around A$3.1 million of new contract wins across New Zealand, Australia and Canada. Longer term, the swing factor is whether Austco can grow the recurring software and SMA base faster than the lumpier hardware line, lifting margin quality and earnings visibility.

Key Risks

Balance against this several genuine risks. Much of the recent revenue growth is project-based and can be uneven quarter to quarter; the order book, or unfilled contracted revenue, was $47.2 million at 16 February 2026, down from $53.8 million reported in August 2025, which bears watching. Part of the growth has come via acquisition, carrying integration and contingent-consideration risk. As a small-cap with limited broker coverage, the stock can be thinly traded and volatile, and currency movements affect a business earning across multiple regions. Recurring…

What does Austco Healthcare (ASX do?

What is the latest development?

What financial or operational point stands out?

What may be watched next?

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.